Relora supplement launch
This article was originally published in The Tan Sheet
Executive Summary
Next Pharmaceuticals in discussions with Pharmavite, Natrol, PureTec for potential distribution of Relora-containing supplements in mass market channels, and with Nutraceutical Corp. for health food store sales. Products expected to be in all distribution channels in 30-60 days, ingredient supplier says. Relora contains proprietary plant extract from Magnolia officinalis and Phellodendron amurense and is manufactured by RJ Reynolds' Avoca division (1"The Tan Sheet" March 20, 2000, In Brief). Next is positioning the ingredient as a kava alternative, says it is "clinically shown to significantly alter the hormone levels associated with stress-induced obesity"...
You may also be interested in...
Joe Camel "supplements" his portfolio
RJ Reynolds Tobacco Company's Avoca division and Next Pharmaceuticals have partnered to develop proprietary dietary supplement ingredients, the firms announce March 8. Flagship Nextracts include the COX-2 anti-inflammatory Nexprofen and Relora, a phenolic complex for anxiety and stress. Others are Standardized Echinacea Purpurea Nextract with 4% phenolic compounds and four Standardized Saw Palmetto Nextracts containing 10%, 25%, 30% and 40% total fatty acids, respectively. The January agreement follows 18 months of R&D; the agricultural and extraction facilities are located at Avoca's 2,400-acre North Carolina facility. Next is courting large pharmaceutical and supplement companies as part of the ingredients' "roll-out" phase
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.